The Zhitong Finance App learned that leading nuclear drugs have brought huge benefits! Recently, GPN01530, a globally innovative FAP target radionuclide conjugate drug (RDC) independently developed by Yuanda Pharmaceutical (00512.HK), was officially approved by the US FDA to conduct phase I/II clinical research to diagnose solid tumors.

The Zhitong Finance App learned that leading nuclear drugs have brought huge benefits! Recently, GPN01530, a globally innovative FAP target radionuclide conjugate drug (RDC) independently developed by Yuanda Pharmaceutical (00512.HK), was officially approved by the US FDA to conduct phase I/II clinical research to diagnose solid tumors.